ADXNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Addex Therapeutics Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on May 15, 2026
$2.89+0.13 (+4.71%)
Close on Oct 19, 2026
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2025 Ended Dec 31, 2025 | Apr 30, 2026 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Apr 25, 2025 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Apr 18, 2024 | Before market open | – | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Mar 30, 2023 | Before market open | – | – | – |
| Q4 FY2021 Ended Dec 31, 2021 | Mar 10, 2022 | Before market open | – | – | – |
Press releases
Announcements Addex Therapeutics filed with the SEC
Addex Therapeutics Announces Executive Management Changes
EX-99.1 to Form 6-K
INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
EX-99.1 to Form 6-K
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
EX-99.2 to Form 6-K
Addex Therapeutics Reports 2026 Half-Year Results
EX-99.3 to Form 6-K
Addex Shareholders Approve All Resolutions at Annual General Meeting
EX-99.1 to Form 6-K
INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED
EX-99.1 to Form 6-K
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
EX-99.2 to Form 6-K
Addex Therapeutics Reports First Quarter 2026
EX-99.3 to Form 6-K
Addex Convenes Annual General Meeting 2026
EX-99.1 to Form 6-K
Addex Reports Full Year 2025 Financial Results and Provides Corporate Update
EX-99.1 to Form 6-K
INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED
EX-99.1 to Form 6-K
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
EX-99.2 to Form 6-K
Reports 2025 Third Quarter Financial Results and Provides Corporate Update
EX-99.3 to Form 6-K
Addex Increases Issued Share Capital to Create Treasury Shares
EX-99.1 to Form 6-K
INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
EX-99.1 to Form 6-K
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
EX-99.2 to Form 6-K
Addex Appoints Bank of New York Mellon as Depositary Bank
EX-99.1 to Form 6-K
Addex Shareholders Approve All Resolutions at Annual General Meeting
EX-99.1 to Form 6-K
INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED
EX-99.1 to Form 6-K
We are a clinical-stage pharmaceutical
EX-99.2 to Form 6-K
Addex Therapeutics Reports Q1 2025 Financial
EX-99.3 to Form 6-K
Addex Reports Full Year 2024 Financial Results and Provides Corporate Update
EX-99.2 to Form 6-K
Addex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149
EX-99.1 to Form 6-K
INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED
EX-99.1 to Form 6-K
Third Quarter 2024 Financial Results and Provides Corporate Update
EX-99.3 to Form 6-K